Eli Lilly has shown that Jaypirca is as good as, if not better than, Johnson & Johnson and AbbVie’s Imbruvica at shrinking certain types of blood cancer in a late-stage trial that enrolled some first …
Day after resigning, Tidmarsh now says he’ll fight exit from FDA
One day after stepping down as CDER Director, George Tidmarsh has said he will fight the investigations into his conduct and is reconsidering his decision.

